FdaApplication
NDA 212905
Identifiers
- fda_app_no: NDA212905
Properties
| Property | Value |
|---|---|
| applicant_name | VERRICA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-07-21 |
Revenue by product
YCANTH
| Period | Revenue |
|---|---|
| Q2 2026 | $5.1M |
| Q1 2026 | $4.3M |
| Q3 2025 | $3.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YCANTH | CANTHARIDIN | 0.7% | SOLUTION;TOPICAL |
1 product